Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages | Digestive Diseases and Sciences
Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine | Scientific Reports
Hepatitis C virus core protein activates proteasomal activator 28 gamma to downregulate p16 levels via ubiquitin-independent proteasomal degradation - ScienceDirect
Hepatitis C virus - Wikipedia
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape - ScienceDirect
Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment - eBioMedicine
Frontiers | Chronic HCV infection promotes cytotoxicity in antigen-specific CD8+ T cells regardless of virus specificity
Galactose Functionalized Mesoporous Silica Nanoparticles As Delivery Vehicle in the Treatment of Hepatitis C Infection | ACS Applied Bio Materials
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions - ScienceDirect
Frontiers | Chronic HCV infection promotes cytotoxicity in antigen-specific CD8+ T cells regardless of virus specificity
Frontiers | Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment
Hepatitis C virus - Wikipedia
Molecules | Free Full-Text | Identification of Potential HCV Inhibitors Based on the Interaction of Epigallocatechin-3-Gallate with Viral Envelope Proteins
HCV virology and diagnosis - ScienceDirect
Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Anti-Viral Effects of Different Medicinal Plants Against Infection | SpringerLink
2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology (Coronary, Peripheral Vascular, and Structural Heart Interventions): A Report of the ACC Competency Management Committee | Circulation: Cardiovascular Interventions
Frontiers | Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape - ScienceDirect
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection - The Lancet
Frontiers | The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019
Frontiers | Chronic HCV infection promotes cytotoxicity in antigen-specific CD8+ T cells regardless of virus specificity
Hepatitis C virus - Wikipedia
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions - ScienceDirect
Sterol O-acyltransferase 2 chaperoned by apolipoprotein J facilitates hepatic lipid accumulation following viral and nutrient stresses | Communications Biology
Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn? | Journal of Medicinal Chemistry
Hepatitis C virus - Wikipedia
Virology and cell biology of the hepatitis C virus life cycle – An update - ScienceDirect
